Phathom spikes as Cantor Fitzgerald bullish on IP claims
Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Phathom Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Maximize Your Portfolio ...
pharmaphorum2y
Takeda spinout Phathom claims its first FDA approvals
Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...
Benzinga.com15d
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Quotes, Forecast and News Summary
Avi Kapoor "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ...
Yahoo Finance20d
Phathom Pharmaceuticals, Inc. (PHAT)
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...
Nasdaq20d
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...